This document provides an overview of Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing targeted radiotherapies for cancer. It discusses Actinium's proprietary alpha particle immunotherapy platform technology, clinical pipeline including lead drug Iomab-B, intellectual property protection, and financial details. The document contains disclaimer language stating that it does not constitute an offer to buy or sell securities and no reliance should be placed on the information provided.
This document provides an overview of Actinium Pharmaceuticals, Inc. and summarizes their proprietary alpha particle immunotherapy technology and product pipeline. Key points include:
1) Actinium has a pipeline of targeted radiotherapy candidates using alpha emitters to treat various blood cancers. Their lead candidate, Iomab-B, is being developed for conditioning blood cancer patients prior to bone marrow transplant.
2) Iomab-B has shown promising results in clinical trials, successfully preparing older refractory AML patients for transplant who otherwise would not be eligible. Actinium has FDA agreement to advance Iomab-B into a Phase III registration trial.
3) Actinium has a proprietary technology
Actinium Pharmaceuticals is a public biotechnology company developing antibody-directed radioisotopes to target cancers. The company presentation provides an overview of Actinium, highlighting its prior clinical data, potential for breakthrough therapies, antibody-directed radioisotope platform, experienced management team, and positioning in the targeted therapy market. It also lists members of the company's clinical advisory board from leading cancer centers who will assist with drug development.
TapImmune Inc. is announcing a $70 million private placement to advance its novel T cell therapy programs through multiple Phase 2 clinical trials in combination with Marker Therapeutics. The financing will also support building out clinical and manufacturing facilities. TapImmune and Marker will combine through a merger, with the combined company focusing on a multi-antigen T cell therapy approach that does not require genetic modification of T cells and has shown durable responses with minimal toxicity compared to other cell therapies in clinical trials so far. The financing is expected to fund the combined company into mid-2021.
2015 Aphria Medical Marijuana Investor PresentationAphriaMMJ
Aphria Inc (TSXV:APH)
Aphria is a licensed producer of Medical Marijuana under the laws of Marijuana for Medical Purposes Regulations.
Aphria is publicly traded on the TSX Venture Exchange under the symbol APH.V
- DecisionPoint Systems is an enterprise mobility solutions provider that has experienced rapid growth, with revenues increasing from $58 million in 2011 to over $71 million in 2012.
- The company provides end-to-end mobile solutions across several vertical markets, including field workforce automation, retail systems, and warehouse distribution.
- DecisionPoint's growth strategy focuses on increasing higher margin software and professional services revenue, penetrating new verticals, leveraging partners, and pursuing acquisitions.
This document provides an overview of Energy Fuels Inc., which is America's premier uranium producer. Energy Fuels aims to become the dominant uranium producer in the US and a mid-tier global producer. It currently has the largest uranium production platform in the US, with production facilities located in Arizona, Utah, Colorado, and Wyoming. The document discusses Energy Fuels' strategy of maintaining prudent production levels in the current weak price environment but positioning itself for growth as uranium prices are expected to rebound with increasing global nuclear energy demand.
NeoStem, Inc. (“NeoStem” or the “Company”), a biopharmaceutical company, is capitalizing on the paradigm shift occurring in medicine by engaging in the development and manufacture of cellular therapies for oncology, immunology, and regenerative medicines in the United States. The Company anticipates that cell therapy will play a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society.
Energy Fuels Inc. is a leading American uranium producer focused on conventional uranium production in the United States. It operates the White Mesa Mill, the only conventional uranium mill operating in the U.S., which produced 1.2 million pounds of U3O8 in 2013. Energy Fuels aims to increase production to over 6 million pounds annually by restarting idled mines and developing new projects as uranium market conditions improve. The company has existing sales contracts with major utilities and seeks to become the dominant uranium producer in the U.S. and a mid-tier global producer.
This document provides an overview of Actinium Pharmaceuticals, Inc. and summarizes their proprietary alpha particle immunotherapy technology and product pipeline. Key points include:
1) Actinium has a pipeline of targeted radiotherapy candidates using alpha emitters to treat various blood cancers. Their lead candidate, Iomab-B, is being developed for conditioning blood cancer patients prior to bone marrow transplant.
2) Iomab-B has shown promising results in clinical trials, successfully preparing older refractory AML patients for transplant who otherwise would not be eligible. Actinium has FDA agreement to advance Iomab-B into a Phase III registration trial.
3) Actinium has a proprietary technology
Actinium Pharmaceuticals is a public biotechnology company developing antibody-directed radioisotopes to target cancers. The company presentation provides an overview of Actinium, highlighting its prior clinical data, potential for breakthrough therapies, antibody-directed radioisotope platform, experienced management team, and positioning in the targeted therapy market. It also lists members of the company's clinical advisory board from leading cancer centers who will assist with drug development.
TapImmune Inc. is announcing a $70 million private placement to advance its novel T cell therapy programs through multiple Phase 2 clinical trials in combination with Marker Therapeutics. The financing will also support building out clinical and manufacturing facilities. TapImmune and Marker will combine through a merger, with the combined company focusing on a multi-antigen T cell therapy approach that does not require genetic modification of T cells and has shown durable responses with minimal toxicity compared to other cell therapies in clinical trials so far. The financing is expected to fund the combined company into mid-2021.
2015 Aphria Medical Marijuana Investor PresentationAphriaMMJ
Aphria Inc (TSXV:APH)
Aphria is a licensed producer of Medical Marijuana under the laws of Marijuana for Medical Purposes Regulations.
Aphria is publicly traded on the TSX Venture Exchange under the symbol APH.V
- DecisionPoint Systems is an enterprise mobility solutions provider that has experienced rapid growth, with revenues increasing from $58 million in 2011 to over $71 million in 2012.
- The company provides end-to-end mobile solutions across several vertical markets, including field workforce automation, retail systems, and warehouse distribution.
- DecisionPoint's growth strategy focuses on increasing higher margin software and professional services revenue, penetrating new verticals, leveraging partners, and pursuing acquisitions.
This document provides an overview of Energy Fuels Inc., which is America's premier uranium producer. Energy Fuels aims to become the dominant uranium producer in the US and a mid-tier global producer. It currently has the largest uranium production platform in the US, with production facilities located in Arizona, Utah, Colorado, and Wyoming. The document discusses Energy Fuels' strategy of maintaining prudent production levels in the current weak price environment but positioning itself for growth as uranium prices are expected to rebound with increasing global nuclear energy demand.
NeoStem, Inc. (“NeoStem” or the “Company”), a biopharmaceutical company, is capitalizing on the paradigm shift occurring in medicine by engaging in the development and manufacture of cellular therapies for oncology, immunology, and regenerative medicines in the United States. The Company anticipates that cell therapy will play a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society.
Energy Fuels Inc. is a leading American uranium producer focused on conventional uranium production in the United States. It operates the White Mesa Mill, the only conventional uranium mill operating in the U.S., which produced 1.2 million pounds of U3O8 in 2013. Energy Fuels aims to increase production to over 6 million pounds annually by restarting idled mines and developing new projects as uranium market conditions improve. The company has existing sales contracts with major utilities and seeks to become the dominant uranium producer in the U.S. and a mid-tier global producer.
Thinspace is a global provider of application delivery, desktop virtualization, and cloud client technology solutions that enable secure application and desktop delivery to any device over any network. The company has 28 staff across offices in the US, UK, India, and Canada. Thinspace develops solutions for customers of all sizes and pursues routes to market through distribution, hosting, and independent software vendors. Its competitors include Citrix but it aims to provide more competitive pricing with reduced time to market and costs through its technology solutions.
Energy Fuels is a uranium mining and milling company with operations in the United States. It owns the only operating conventional uranium mill in the US and has a large portfolio of uranium projects. The company is pursuing a strategy of low-cost production while conserving capital in the current weak uranium market. It aims to grow production significantly if uranium prices strengthen in the future.
Envision Solar International is a company that designs, markets, and deploys solar energy products for parking structures. Their products include the Solar Tree structure that shades multiple parking spaces, the Solar Tree Socket that shades a single space, and the EV ARC transportable solar-powered electric vehicle charger. The company aims to leverage these products to access the large markets for solar-shaded parking and electric vehicle charging. They see opportunities to scale production efficiently and achieve significant operating leverage as markets and sales grow over the next few years. The management team has experience in renewable energy, infrastructure deployment, and public companies.
CUI Global presented an overview of its business and recent acquisition of Orbital Gas Systems. CUI provides enabling technologies to industries including energy, healthcare, and networking. It has a dynamic base business and is pursuing disruptive innovations like gas measurement devices. The acquisition of Orbital, a natural gas solutions provider, creates strategic synergies and a combined solution to address gas quality measurement. Management believes the combined company is well positioned for growth with opportunities in the large natural gas market.
GlyEco is an innovative green chemistry company that recycles glycol using a patented process. It transforms hazardous waste glycol into profitable recycled glycol products. The company has acquired several existing glycol recyclers and plans to integrate them and expand globally. Glycol recycling is an emerging industry with significant growth potential as GlyEco can process all five major types of waste glycol streams to produce high quality recycled glycol.
VeriTeQ provides proprietary healthcare solutions including implantable radio frequency microchip technology cleared by the FDA. The document discusses VeriTeQ's unique value in enabling compliance with an FDA Final Rule requiring medical devices to carry a direct part marking through automatic identification and data capture technology. It also summarizes VeriTeQ's product portfolio in medical device identification, bio-sensing technologies, target markets, and financial projections showing significant revenue growth potential over the next five years.
AV Therapeutics is developing Capridine, a patented drug that shows promise for treating prostate cancer. Preclinical studies found Capridine to be effective against taxane-resistant prostate cancer with minimal toxicity. The company plans to manufacture and formulate Capridine under GMP and conduct toxicology studies to file an IND and begin phase I/II clinical trials. AV Therapeutics is led by a team of renowned oncologists and scientists from top institutions and has scientific and medical advisors supporting its work developing Capridine as a new targeted therapy for prostate cancer.
This document provides a summary of statements made in a presentation by VeriTeQ Corporation. It includes forward-looking statements about VeriTeQ's proposed name change, reverse stock split, commercialization activities, market opportunities, strategy, competition, FDA regulation, and partnership opportunities. The document cautions that VeriTeQ's actual results could differ from these statements due to various risks and uncertainties. It also provides background on VeriTeQ, including its acquisition of intellectual property for implantable RFID technology in healthcare. The document summarizes VeriTeQ's business areas in medical device UDI compliance and biosensing technologies for radiation dosimetry.
This document summarizes a corporate presentation for Galectin Therapeutics. It provides an overview of the company and its clinical-stage drug candidates that target galectin proteins to treat fibrotic diseases and cancer. Key points include:
- Galectin Therapeutics is developing inhibitors of galectin-3 to treat conditions like liver fibrosis and cancer.
- Their lead candidate, GR-MD-02, is in a Phase 1 clinical trial for liver fibrosis associated with NASH. Results from the first cohort showed declines in fibrosis biomarkers, suggesting regression of fibrosis.
- The presentation reviews the large unmet medical need in treating liver fibrosis and NASH, the development program for GR-MD-
This document provides an overview of Quadrant 4 System Corporation and its business. It summarizes the company's products and services which focus on social, mobile, analytics and cloud technologies. Key points include that Q4 expects over $50 million in revenue in 2014 through organic growth of existing products like its retail and healthcare platforms. It is focused on capitalizing on digital disruptions across industries through its technology stack and growth strategy of expanding customer base, products and strategic acquisitions.
Galectin Therapeutics is developing novel drug compounds that inhibit galectin proteins to treat fibrotic diseases and cancer. Their lead drug candidate, GR-MD-02, is currently in clinical trials for liver fibrosis associated with non-alcoholic steatohepatitis (NASH) and metastatic melanoma. NASH affects an estimated 6 million people in the US with advanced liver fibrosis, representing a major unmet medical need. Data from animal and early human studies suggest that GR-MD-02 can reduce liver inflammation and fibrosis. Galectin Therapeutics is focused on developing GR-MD-02 for the indication of NASH with advanced liver fibrosis.
NanoViricides is developing nanomedicine-based drugs to treat various viral diseases like influenza, HIV, hepatitis C, and Ebola. The company has 9 drug candidates in development that have shown safety and efficacy in animal studies. NanoViricides' first drug to enter human trials will be FluCide for influenza, which completely protected animals against lethal viral exposure without toxicity.
StarStream Entertainment is a theatrical motion picture production and financing company focused on producing and financing edgy, high quality motion pictures with strong cast and lean budgets for a commercial audience.
The Coin Tree is a cloud-based platform that provides storage, insurance, and payment processing for bitcoin, leveraging advanced security. It aims to serve the growing virtual currency community by solving issues around accessibility, security, liquidity, and adoption of bitcoin.
Actinium Pharmaceuticals is developing targeted alpha therapies for cancer including Iomab-B and Actimab-A. Interim results from the ongoing Phase I/II trial of Actimab-A show it has eliminated peripheral blasts in 67% of patients and decreased bone marrow blasts by at least 50% in 53% of patients, with 20% of patients achieving bone marrow blasts of 5% or less. These results support further development of Actimab-A as a potential low intensity treatment for elderly acute myeloid leukemia patients.
A public biotechnology company using world
class science to develop and commercialize
antibody directed radioisotopes to target
unmet medical needs in cancer
- Liquid biopsy from a simple blood test enables personalized cancer care by harvesting rare cancer cells from blood using ANGLE's patented Parsortix system.
- The Parsortix system captures circulating tumor cells shed from primary tumors with unprecedented sensitivity and specificity, enabling non-invasive analysis and repeat testing over time for personalized treatment.
- ANGLE aims to partner with established diagnostic companies to accelerate global distribution of the Parsortix system and make liquid biopsy available for improving cancer care and reducing healthcare costs.
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...ANGLE plc
Liquid biopsy from a simple blood test is enabling personalised cancer care. The Parsortix system from ANGLE can harvest cancer cells from blood (liquid biopsy) in a non-invasive and repeatable way. This provides a new approach to obtaining cancer cells for analysis compared to traditional tumour biopsies. Key opinion leaders have evaluated the Parsortix system and found that it captures all types of cancer cells with high purity in an easy to use process, making it well suited for clinical applications in personalised cancer care.
Presentation 28 July 2015: Preliminary Results for the year ended 30 April 2015ANGLE plc
ANGLE reported encouraging results in ovarian cancer patients and strengthened relationships with six world-class cancer centers. The company initiated two corporate collaborations and remains on track for first research use sales this year to support drug trials. ANGLE's liquid biopsy technology shows promise for advancing precision cancer treatment through non-invasive analysis of circulating tumor cells in blood samples.
ANGLE shares investor evening 15 April 2015ANGLE plc
ANGLE has developed a liquid biopsy system called Parsortix that can isolate circulating tumor cells from blood samples in a non-invasive manner. Early clinical studies have shown the system to have unprecedented sensitivity and specificity in detecting ovarian cancer. ANGLE is working with key opinion leaders to validate Parsortix and develop clinical applications in other cancers that could lead to regulatory approval and access to multi-billion dollar clinical markets.
EVT was founded with a vision of championing the joy of motoring in an electric world. As the planet undergoes an ‘EV revolution’ and becomes more green, we believe some of the ‘joy’ of motoring has been lost along the way in the design and character of early electric vehicle brands that have come to market.
Given this, at EVT our ‘big idea’ is that we can electrify iconic driving experiences, helping iconic, luxury and classic brands go electric. We believe this will help accelerate the EV revolution as drivers who might otherwise be further back on the EV adoption curve can get behind the wheel of beloved brands that we help go electric.
We believe this big idea will create value for our shareholders as we own iconic motoring brands, controlling manufacturing and deriving full value from the total customer experience.
- Ping An Healthcare and Technology Company Limited is a leading integrated healthcare and technology company in China.
- It operates a one-stop healthcare platform that connects users to online and offline medical resources through telemedicine services, health management programs, and a health mall.
- The company has a large user base of over 192 million registered users and leverages technologies like AI to enhance user experience and provide 24/7 on-demand healthcare services.
Thinspace is a global provider of application delivery, desktop virtualization, and cloud client technology solutions that enable secure application and desktop delivery to any device over any network. The company has 28 staff across offices in the US, UK, India, and Canada. Thinspace develops solutions for customers of all sizes and pursues routes to market through distribution, hosting, and independent software vendors. Its competitors include Citrix but it aims to provide more competitive pricing with reduced time to market and costs through its technology solutions.
Energy Fuels is a uranium mining and milling company with operations in the United States. It owns the only operating conventional uranium mill in the US and has a large portfolio of uranium projects. The company is pursuing a strategy of low-cost production while conserving capital in the current weak uranium market. It aims to grow production significantly if uranium prices strengthen in the future.
Envision Solar International is a company that designs, markets, and deploys solar energy products for parking structures. Their products include the Solar Tree structure that shades multiple parking spaces, the Solar Tree Socket that shades a single space, and the EV ARC transportable solar-powered electric vehicle charger. The company aims to leverage these products to access the large markets for solar-shaded parking and electric vehicle charging. They see opportunities to scale production efficiently and achieve significant operating leverage as markets and sales grow over the next few years. The management team has experience in renewable energy, infrastructure deployment, and public companies.
CUI Global presented an overview of its business and recent acquisition of Orbital Gas Systems. CUI provides enabling technologies to industries including energy, healthcare, and networking. It has a dynamic base business and is pursuing disruptive innovations like gas measurement devices. The acquisition of Orbital, a natural gas solutions provider, creates strategic synergies and a combined solution to address gas quality measurement. Management believes the combined company is well positioned for growth with opportunities in the large natural gas market.
GlyEco is an innovative green chemistry company that recycles glycol using a patented process. It transforms hazardous waste glycol into profitable recycled glycol products. The company has acquired several existing glycol recyclers and plans to integrate them and expand globally. Glycol recycling is an emerging industry with significant growth potential as GlyEco can process all five major types of waste glycol streams to produce high quality recycled glycol.
VeriTeQ provides proprietary healthcare solutions including implantable radio frequency microchip technology cleared by the FDA. The document discusses VeriTeQ's unique value in enabling compliance with an FDA Final Rule requiring medical devices to carry a direct part marking through automatic identification and data capture technology. It also summarizes VeriTeQ's product portfolio in medical device identification, bio-sensing technologies, target markets, and financial projections showing significant revenue growth potential over the next five years.
AV Therapeutics is developing Capridine, a patented drug that shows promise for treating prostate cancer. Preclinical studies found Capridine to be effective against taxane-resistant prostate cancer with minimal toxicity. The company plans to manufacture and formulate Capridine under GMP and conduct toxicology studies to file an IND and begin phase I/II clinical trials. AV Therapeutics is led by a team of renowned oncologists and scientists from top institutions and has scientific and medical advisors supporting its work developing Capridine as a new targeted therapy for prostate cancer.
This document provides a summary of statements made in a presentation by VeriTeQ Corporation. It includes forward-looking statements about VeriTeQ's proposed name change, reverse stock split, commercialization activities, market opportunities, strategy, competition, FDA regulation, and partnership opportunities. The document cautions that VeriTeQ's actual results could differ from these statements due to various risks and uncertainties. It also provides background on VeriTeQ, including its acquisition of intellectual property for implantable RFID technology in healthcare. The document summarizes VeriTeQ's business areas in medical device UDI compliance and biosensing technologies for radiation dosimetry.
This document summarizes a corporate presentation for Galectin Therapeutics. It provides an overview of the company and its clinical-stage drug candidates that target galectin proteins to treat fibrotic diseases and cancer. Key points include:
- Galectin Therapeutics is developing inhibitors of galectin-3 to treat conditions like liver fibrosis and cancer.
- Their lead candidate, GR-MD-02, is in a Phase 1 clinical trial for liver fibrosis associated with NASH. Results from the first cohort showed declines in fibrosis biomarkers, suggesting regression of fibrosis.
- The presentation reviews the large unmet medical need in treating liver fibrosis and NASH, the development program for GR-MD-
This document provides an overview of Quadrant 4 System Corporation and its business. It summarizes the company's products and services which focus on social, mobile, analytics and cloud technologies. Key points include that Q4 expects over $50 million in revenue in 2014 through organic growth of existing products like its retail and healthcare platforms. It is focused on capitalizing on digital disruptions across industries through its technology stack and growth strategy of expanding customer base, products and strategic acquisitions.
Galectin Therapeutics is developing novel drug compounds that inhibit galectin proteins to treat fibrotic diseases and cancer. Their lead drug candidate, GR-MD-02, is currently in clinical trials for liver fibrosis associated with non-alcoholic steatohepatitis (NASH) and metastatic melanoma. NASH affects an estimated 6 million people in the US with advanced liver fibrosis, representing a major unmet medical need. Data from animal and early human studies suggest that GR-MD-02 can reduce liver inflammation and fibrosis. Galectin Therapeutics is focused on developing GR-MD-02 for the indication of NASH with advanced liver fibrosis.
NanoViricides is developing nanomedicine-based drugs to treat various viral diseases like influenza, HIV, hepatitis C, and Ebola. The company has 9 drug candidates in development that have shown safety and efficacy in animal studies. NanoViricides' first drug to enter human trials will be FluCide for influenza, which completely protected animals against lethal viral exposure without toxicity.
StarStream Entertainment is a theatrical motion picture production and financing company focused on producing and financing edgy, high quality motion pictures with strong cast and lean budgets for a commercial audience.
The Coin Tree is a cloud-based platform that provides storage, insurance, and payment processing for bitcoin, leveraging advanced security. It aims to serve the growing virtual currency community by solving issues around accessibility, security, liquidity, and adoption of bitcoin.
Actinium Pharmaceuticals is developing targeted alpha therapies for cancer including Iomab-B and Actimab-A. Interim results from the ongoing Phase I/II trial of Actimab-A show it has eliminated peripheral blasts in 67% of patients and decreased bone marrow blasts by at least 50% in 53% of patients, with 20% of patients achieving bone marrow blasts of 5% or less. These results support further development of Actimab-A as a potential low intensity treatment for elderly acute myeloid leukemia patients.
A public biotechnology company using world
class science to develop and commercialize
antibody directed radioisotopes to target
unmet medical needs in cancer
- Liquid biopsy from a simple blood test enables personalized cancer care by harvesting rare cancer cells from blood using ANGLE's patented Parsortix system.
- The Parsortix system captures circulating tumor cells shed from primary tumors with unprecedented sensitivity and specificity, enabling non-invasive analysis and repeat testing over time for personalized treatment.
- ANGLE aims to partner with established diagnostic companies to accelerate global distribution of the Parsortix system and make liquid biopsy available for improving cancer care and reducing healthcare costs.
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...ANGLE plc
Liquid biopsy from a simple blood test is enabling personalised cancer care. The Parsortix system from ANGLE can harvest cancer cells from blood (liquid biopsy) in a non-invasive and repeatable way. This provides a new approach to obtaining cancer cells for analysis compared to traditional tumour biopsies. Key opinion leaders have evaluated the Parsortix system and found that it captures all types of cancer cells with high purity in an easy to use process, making it well suited for clinical applications in personalised cancer care.
Presentation 28 July 2015: Preliminary Results for the year ended 30 April 2015ANGLE plc
ANGLE reported encouraging results in ovarian cancer patients and strengthened relationships with six world-class cancer centers. The company initiated two corporate collaborations and remains on track for first research use sales this year to support drug trials. ANGLE's liquid biopsy technology shows promise for advancing precision cancer treatment through non-invasive analysis of circulating tumor cells in blood samples.
ANGLE shares investor evening 15 April 2015ANGLE plc
ANGLE has developed a liquid biopsy system called Parsortix that can isolate circulating tumor cells from blood samples in a non-invasive manner. Early clinical studies have shown the system to have unprecedented sensitivity and specificity in detecting ovarian cancer. ANGLE is working with key opinion leaders to validate Parsortix and develop clinical applications in other cancers that could lead to regulatory approval and access to multi-billion dollar clinical markets.
EVT was founded with a vision of championing the joy of motoring in an electric world. As the planet undergoes an ‘EV revolution’ and becomes more green, we believe some of the ‘joy’ of motoring has been lost along the way in the design and character of early electric vehicle brands that have come to market.
Given this, at EVT our ‘big idea’ is that we can electrify iconic driving experiences, helping iconic, luxury and classic brands go electric. We believe this will help accelerate the EV revolution as drivers who might otherwise be further back on the EV adoption curve can get behind the wheel of beloved brands that we help go electric.
We believe this big idea will create value for our shareholders as we own iconic motoring brands, controlling manufacturing and deriving full value from the total customer experience.
- Ping An Healthcare and Technology Company Limited is a leading integrated healthcare and technology company in China.
- It operates a one-stop healthcare platform that connects users to online and offline medical resources through telemedicine services, health management programs, and a health mall.
- The company has a large user base of over 192 million registered users and leverages technologies like AI to enhance user experience and provide 24/7 on-demand healthcare services.
Presentation 2 July 2015: Proactive Investors Forum ANGLE plc
ANGLE presented on their Parsortix liquid biopsy system, a non-invasive method to capture and harvest circulating tumor cells from blood to enable personalized cancer care. Their system has shown promising results in early clinical studies and key opinion leader evaluations, and ANGLE outlined their commercialization strategy focused on research use sales and the first clinical application in ovarian cancer triage.
Max Healthcare Institute Limited's investor presentation provides an overview of the company and its growth drivers. It highlights the following key points in 3 sentences:
Max Healthcare is India's second largest hospital chain in terms of revenue, EBITDA and market capitalization, with a dominant presence in the largest and most profitable markets of Delhi NCR and Mumbai. It has a vision to be the most well regarded healthcare provider in India committed to clinical excellence, cutting edge technology, and research. The presentation outlines Max Healthcare's track record, strategic focus areas, and financial performance to position it for continued strong growth and profitable expansion.
- PharmAust is developing a proprietary pipeline of clinical-stage oncology drugs focused on drug repurposing, with its lead product PPL-1 (Monepantel-MPL) successfully completing Phase I/II trials and now ready for Phase II trials.
- MPL has demonstrated safety and activity against cancer markers in humans, as well as synergy with other drugs, and has the potential to treat cancers where standard therapies have failed.
- MPL is already approved for veterinary cancer applications through a partnership with Novartis Animal Health, providing validation of its mechanism of action and safety profile.
PharmAust is a clinical-stage oncology company focused on drug repurposing. Its lead product PPL-1 (Monepantel-MPL) successfully completed Phase I/II trials and is now Phase II ready. MPL has potential as a new class of targeted anti-cancer therapy. PharmAust also has a profitable specialty chemicals business and options for veterinary cancer applications through partnerships. The company is significantly undervalued given its pipeline and clinical progress.
EV Technology Group is a company that aims to electrify iconic automotive brands. It has acquired MOKE International, the owner of the iconic MOKE brand, and has begun customer deliveries of its new Electric MOKE in June 2022. The company also recently agreed to acquire up to 100% of Fablink Group, a UK-based tier one automotive manufacturing and supply chain company, to support its electrification strategy. EV Technology Group is led by an experienced team with expertise in automotive, manufacturing, and branding/design.
- Caribbean sovereign bonds performed well in Q2 2015, with credit spreads tightening as economic conditions improved due to lower energy prices boosting tourism.
- Barbados showed significant fiscal improvement but more work is needed to reduce expenditures and stimulate growth. The Bahamas faces challenges from the bankruptcy of the large Baha Mar resort project.
- Jamaica and the Dominican Republic continue to consolidate fiscal gains from IMF programs. The outlook remains positive despite the potential for US rate hikes, and Caribbean bonds are recommended with the exception of Costa Rica.
EV Technology Group Ltd owns and operates iconic and luxury motoring brands and helps them 'go electric. It acquires iconic brands and invests in making the transition to electric.
Valour is a digital asset investment firm that allows traditional investors to identify and invest in a diversified
portfolio of digital assets across the decentralized finance, Web 3.0 and gaming sector. We capture the
upside in the explosive growth of the regulated Web 3.0 & future of gaming space via regulated equity
wrappers and a strategic partnership and ownership stake in SEBA Bank AG, a regulated crypto bank. We
are the only publicly traded company built to give investors direct exposure to these nascent markets.
Marshall Motor Holdings PLC is planning an initial public offering (IPO) and admission to trading on the AIM market of the London Stock Exchange. The company will issue 26,845,638 new ordinary shares at 149 pence per share through a placing to raise approximately £36.9 million. Upon completion of the placing and admission to AIM, Marshall Motor Holdings will have 77,236,263 ordinary shares issued and fully paid, with a market capitalization of approximately £115.1 million. The proceeds from the share placing will be used for general corporate purposes. Admission to AIM is expected to become effective on April 2, 2015.
EV Technology Group Ltd owns and operates iconic and luxury motoring brands and helps them 'go electric. It acquires iconic brands and invests in making the transition to electric.
Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...RedChip Companies, Inc.
This document provides an overview of Big North Graphite Corp., a mining company exploring graphite opportunities in Mexico and Canada. It summarizes the management team's experience, the capital structure including shares outstanding and warrants, and key investment highlights. Specifically, it notes Big North is currently selling amorphous graphite in Mexico and aims to restart near-term flake graphite production at its recently acquired El Tejon Flake Graphite Mine and Mill in Oaxaca, Mexico, which was previously operational until 2002. A cautionary note also indicates forward-looking statements may materially differ from expectations.
“The Coin Tree is a cloud-based storage, insurance, and payment processing platform for bitcoin that leverages cutting edge transactional security to serve the ever expanding virtual currency community."
StarStream Entertainment is a theatrical motion picture production and financing company focused on producing and financing edgy, high quality motion pictures with strong cast and lean budgets for a commercial audience.
StarStream Entertainment aims to be a theatrical motion picture production and financing company focused on producing edgy, high quality films with strong casts and lean budgets. It mitigates risk through fiscal precision by financing projects once they are fully developed and ready to produce, offering investors a quicker return. Recent successful films include Lee Daniels' The Butler, Life of Crime, and Life After Beth.
Cancer Genetics provides personalized cancer treatment through molecular diagnostic testing. They have launched 6 proprietary diagnostic products targeting hematological and urogenital cancers. Their tests help determine cancer type and prognosis, guiding treatment selection. Recent acquisitions expand their capabilities and access to new markets in India. Their business model provides clinical testing services to oncologists and biopharma partnerships to support drug development.
- Bitcoin Shop is one of the first publicly traded companies focused on the virtual currency ecosystem. It operates an ecommerce platform that accepts bitcoin and other cryptocurrencies as payment.
- The company is developing its BTCS 2.0 platform to expand its product offerings and vendor base. It aims to build a virtual currency ecosystem through ecommerce.
- Bitcoin Shop has a experienced management team with expertise in capital markets, technology, and the virtual currency industry. It plans to grow its customer base and monetize through additional service offerings.
InterCloud Systems provides cloud-centric solutions and services to enterprises and service providers. Their two main business focus areas are Software Defined Enterprise and Cloud to Cloud Mobility. They help customers modernize infrastructure, develop cloud strategies, and deliver cloud-centric IT visions aligned to business value. InterCloud partners with major cloud platform and solution providers like VMware, OpenStack, and CloudStack.
This presentation provides an overview of SANUWAVE Health Inc., a regenerative medicine company developing non-invasive biological response activation devices. SANUWAVE's lead product, dermaPACE, is in a Phase III FDA trial for treating diabetic foot ulcers and has the potential for approval in 2015 pending positive results. DermaPACE offers a lower-cost, non-invasive alternative to existing wound therapies. If approved, dermaPACE could address the large diabetic foot ulcer market and be expanded to other applications. SANUWAVE completed a $9.3 million capital raise to fund the dermaPACE trial and has 38 patents covering its shockwave technology platform.
Genius Brands International is a company focused on providing children's entertainment content with purpose for toddlers to tweens. It was created through the merger of A Squared Entertainment and Genius Brands. The document discusses Genius Brands' plans to grow its portfolio of animated properties like Baby Genius, Warren Buffett's Secret Millionaires Club, and new shows in partnership with Stan Lee and Martha Stewart. It aims to distribute this content across television, online, mobile and through a new streaming service, while supporting the content through consumer products licensing. The management team, including Andy and Amy Heyward, have decades of experience in the children's entertainment industry.
StationDigital is a digital media and ecommerce platform that allows users to stream or access any media and purchase digital and physical goods from any device. It has grown rapidly since its public beta launch in 2013, achieving over 1.3 million mobile users. The presentation outlines StationDigital's mission and growth strategy, competitive advantages over other media companies, and large market opportunity in digital media and ecommerce. It argues that StationDigital is well positioned for continued growth and market share capture.
DRONE Aviation Corp (DRNE) was formed in April 2014 to penetrate the rapidly growing Unmanned Aerial Systems (UAS) business in U.S. and abroad for government and commercial customers.
DRNE’s mission is to aggressively penetrate the expanding Drone market with our unique Tethered Drones, which are currently being fielded to the U.S. Department of Defense and State and Local municipalities.
DRNE owns and operates Florida-based Lighter Than Air Systems Corp (LTAS), a developer and supplier of unique and specialized aerial solutions to the U.S. Government, State municipalities, and commercial entities.
InterCloud Systems Incorporated is a single - source provider of end - to - end IT technology and telecom solutions to the ent erprise, service provider, and g overnment markets through “Cloud Platforms” and professional services. “Cloud Comput ing”, is defined as the use of computing resources (compute, NTK, Storage) that are delivered as a managed service over a network. InterCloud offers its service provider custo mers the ability to utilize “cloud” solutions inside their existing network footp rint as well as in a “white label environment” so it can offer a suite of cloud products under their own brand, delivered over the broadband services it presently sell s . ICLD’s cloud services include infrastructure as a service (IaaS), platform as a servi ce (PaaS), and software as a service (SaaS) .
The nuclear energy industry has lain stagnant for over 30 years and has suffered from missteps and perception issues.
Lightbridge is here to innovate and change the conversation. About: Lightbridge is a U.S. nuclear energy company based in McLean, Virginia with operations in Abu Dhabi, Moscow and London. The Company develops proprietary, proliferation resistant, next generation nuclear fuel technologies for current and future nuclear reactor systems. The Company also provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence. Lightbridge's breakthrough fuel technology is establishing new global standards for safe and clean nuclear power and leading the way to a sustainable energy future. Lightbridge consultants provide integrated strategic advice and expertise across a range of disciplines including regulatory affairs, nuclear reactor procurement and deployment, reactor and fuel technology and international relations. The Company leverages those broad and integrated capabilities by offering its services to commercial entities and governments with a need to establish or expand nuclear industry capabilities and infrastructure.
Richfield Oil & Gas Company (OTCQX: ROIL) is an independent exploration and production company headquartered in Salt Lake City, Utah. The Company’s current oil production flows from wells in fields located in Kansas and Wyoming. In addition to several thousand acres in Kansas, Richfield also owns strategically-located exploratory leases in central Utah on trend to major oil discoveries.
American Water provides water and wastewater services to approximately 14 million people in 16 states, has a market capitalization of $8.6 billion, and seeks to continue growing its regulated water business through capital investments and acquisitions while also expanding its complementary market-based business lines. The company has delivered strong total shareholder returns since its 2008 IPO and maintains a transparent dividend policy aimed at increasing its dividend in line with normalized earnings per share growth.
Exeo Entertainment, Inc. is a manufacturing company concentrating on developing innovative products that fill a clearly defined need in today’s interactive entertainment industry. Featured products include the Zaaz™ smart TV keyboards, Patented Psyko Krypton™ 5.1 gaming headphones, Krankz Bluetooth music headphones, an Android® based portable gaming system, and the Extreme Gamer® -the world’s first multi–disc game changer.
Direct Insite (“DIRI”) provides cloud-based, ERP-agnostic solutions that automate Accounts Payable (AP) and Accounts Receivable (AR) invoice processes for Global 3000 companies. Their solutions include invoice validation, order matching, consolidation, dispute handling and e-payment processing. DIRI helps clients eliminate manual processes and costs associated with doing everything on paper. By migrating from paper to electronic, DIRI can reduce transactions costs 50-70% and reduce time by 80%. Current clients include Siemens, HP, IBM, Saint-Gobain, Shell Oil, and Hyatt with a Global vendor network of 350,000+ suppliers.
Lattice Incorporated (“Lattice” or the “Company”), founded in 1973, provides secure communications and information technology, specializing in deploying advanced technology and services to create innovative, cost - effective solutions for the Company’s global customers. The Company provides both wholesale and direct services to correctional facilities and their service providers in the U.S., Canada and Europe. Expansion of Lattice’s direct and wholesale services, including increased techno logy equipment and software sales to wholesale customers, is expected to drive revenue growth and increased margins in the quarters ahead
Quadrant 4 Systems Corporation is a leading provider in of health exchange platforms, innovative software products and proprietary SMAC (social media, mobility, analytics and cloud computing) solutions to enterprise clients in Retail and Manufacturing, Media and Publishing, Financial Services and Health Care sectors.
Energy Fuels is the nation's leading conventional uranium producer, supplying approximately 25% of the uranium produced in the U.S. (based on FY-2013 deliveries). The Company also has the capability to be a significant producer of vanadium. Energy Fuels owns and operates the White Mesa Mill, which is the only conventional uranium mill currently operating in the U.S. The mill is capable of processing 2,000 tons per day of uranium ore and producing up to 8 million lbs. of U3O8 per year (depending on ore grade).
Part 2 Deep Dive: Navigating the 2024 Slowdownjeffkluth1
Introduction
The global retail industry has weathered numerous storms, with the financial crisis of 2008 serving as a poignant reminder of the sector's resilience and adaptability. However, as we navigate the complex landscape of 2024, retailers face a unique set of challenges that demand innovative strategies and a fundamental shift in mindset. This white paper contrasts the impact of the 2008 recession on the retail sector with the current headwinds retailers are grappling with, while offering a comprehensive roadmap for success in this new paradigm.
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdfthesiliconleaders
In the recent edition, The 10 Most Influential Leaders Guiding Corporate Evolution, 2024, The Silicon Leaders magazine gladly features Dejan Štancer, President of the Global Chamber of Business Leaders (GCBL), along with other leaders.
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Final ank Satta Matka Dpbos Final ank Satta Matta Matka 143 Kalyan Matka Guessing Final Matka Final ank Today Matka 420 Satta Batta Satta 143 Kalyan Chart Main Bazar Chart vip Matka Guessing Dpboss 143 Guessing Kalyan night
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Tastemy Pandit
Know what your zodiac sign says about your taste in food! Explore how the 12 zodiac signs influence your culinary preferences with insights from MyPandit. Dive into astrology and flavors!
Taurus Zodiac Sign: Unveiling the Traits, Dates, and Horoscope Insights of th...my Pandit
Dive into the steadfast world of the Taurus Zodiac Sign. Discover the grounded, stable, and logical nature of Taurus individuals, and explore their key personality traits, important dates, and horoscope insights. Learn how the determination and patience of the Taurus sign make them the rock-steady achievers and anchors of the zodiac.
Storytelling is an incredibly valuable tool to share data and information. To get the most impact from stories there are a number of key ingredients. These are based on science and human nature. Using these elements in a story you can deliver information impactfully, ensure action and drive change.
SATTA MATKA SATTA FAST RESULT KALYAN TOP MATKA RESULT KALYAN SATTA MATKA FAST RESULT MILAN RATAN RAJDHANI MAIN BAZAR MATKA FAST TIPS RESULT MATKA CHART JODI CHART PANEL CHART FREE FIX GAME SATTAMATKA ! MATKA MOBI SATTA 143 spboss.in TOP NO1 RESULT FULL RATE MATKA ONLINE GAME PLAY BY APP SPBOSS
IMPACT Silver is a pure silver zinc producer with over $260 million in revenue since 2008 and a large 100% owned 210km Mexico land package - 2024 catalysts includes new 14% grade zinc Plomosas mine and 20,000m of fully funded exploration drilling.
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.AnnySerafinaLove
This letter, written by Kellen Harkins, Course Director at Full Sail University, commends Anny Love's exemplary performance in the Video Sharing Platforms class. It highlights her dedication, willingness to challenge herself, and exceptional skills in production, editing, and marketing across various video platforms like YouTube, TikTok, and Instagram.
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...my Pandit
Explore the fascinating world of the Gemini Zodiac Sign. Discover the unique personality traits, key dates, and horoscope insights of Gemini individuals. Learn how their sociable, communicative nature and boundless curiosity make them the dynamic explorers of the zodiac. Dive into the duality of the Gemini sign and understand their intellectual and adventurous spirit.
Building Your Employer Brand with Social MediaLuanWise
Presented at The Global HR Summit, 6th June 2024
In this keynote, Luan Wise will provide invaluable insights to elevate your employer brand on social media platforms including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok. You'll learn how compelling content can authentically showcase your company culture, values, and employee experiences to support your talent acquisition and retention objectives. Additionally, you'll understand the power of employee advocacy to amplify reach and engagement – helping to position your organization as an employer of choice in today's competitive talent landscape.
How MJ Global Leads the Packaging Industry.pdfMJ Global
MJ Global's success in staying ahead of the curve in the packaging industry is a testament to its dedication to innovation, sustainability, and customer-centricity. By embracing technological advancements, leading in eco-friendly solutions, collaborating with industry leaders, and adapting to evolving consumer preferences, MJ Global continues to set new standards in the packaging sector.
[To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
This PowerPoint compilation offers a comprehensive overview of 20 leading innovation management frameworks and methodologies, selected for their broad applicability across various industries and organizational contexts. These frameworks are valuable resources for a wide range of users, including business professionals, educators, and consultants.
Each framework is presented with visually engaging diagrams and templates, ensuring the content is both informative and appealing. While this compilation is thorough, please note that the slides are intended as supplementary resources and may not be sufficient for standalone instructional purposes.
This compilation is ideal for anyone looking to enhance their understanding of innovation management and drive meaningful change within their organization. Whether you aim to improve product development processes, enhance customer experiences, or drive digital transformation, these frameworks offer valuable insights and tools to help you achieve your goals.
INCLUDED FRAMEWORKS/MODELS:
1. Stanford’s Design Thinking
2. IDEO’s Human-Centered Design
3. Strategyzer’s Business Model Innovation
4. Lean Startup Methodology
5. Agile Innovation Framework
6. Doblin’s Ten Types of Innovation
7. McKinsey’s Three Horizons of Growth
8. Customer Journey Map
9. Christensen’s Disruptive Innovation Theory
10. Blue Ocean Strategy
11. Strategyn’s Jobs-To-Be-Done (JTBD) Framework with Job Map
12. Design Sprint Framework
13. The Double Diamond
14. Lean Six Sigma DMAIC
15. TRIZ Problem-Solving Framework
16. Edward de Bono’s Six Thinking Hats
17. Stage-Gate Model
18. Toyota’s Six Steps of Kaizen
19. Microsoft’s Digital Transformation Framework
20. Design for Six Sigma (DFSS)
To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations
Navigating the world of forex trading can be challenging, especially for beginners. To help you make an informed decision, we have comprehensively compared the best forex brokers in India for 2024. This article, reviewed by Top Forex Brokers Review, will cover featured award winners, the best forex brokers, featured offers, the best copy trading platforms, the best forex brokers for beginners, the best MetaTrader brokers, and recently updated reviews. We will focus on FP Markets, Black Bull, EightCap, IC Markets, and Octa.
1. Actinium Pharmaceuticals, Inc.
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
April 2014
Company Presentation
Ticker: ATNM
(NYSE MKT)
2. 2
Disclaimer and Safe Harbor Statement
Disclaimer
The contents of this presentation and the information which you are given at the time of these slides and the presentation have not been approved
by an authorized person within the meaning of the Financial Services and Markets Act 2000 (the “Act”). Reliance on this presentation and its slides
for the purpose of engaging in investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any
securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in
connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in
these slides or presentation and/or opinions therein. These slides and the presentation are exempt from the general restriction (in section 21 of the
Act) on the communication of invitations or inducements to engage in investment activity on the grounds that it is made to: (a) persons who have
professional experience in matters relating to investments who fall within Article 19(1) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the “Order”); or (b) high net worth entities and other persons to whom it may otherwise lawfully be communicated, falling
within Article 49(1) of the Order (all such persons together being referred to as “relevant persons”). Any person who is not a relevant person should
not rely on this presentation or any of its contents and all persons (whether relevant persons or otherwise) are recommended to seek their own
independent financial advice from a person authorized for the purposes of the Act before engaging in any investment activity involving the
Company’s securities.
Safe Harbor Statement
This presentation contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the private securities litigation
reform act of 1995. Such forward-looking information and statements are based on the current estimates and projections of the Company or
assumptions based on information currently available to the Company. Such statements involve known and unknown risks, uncertainties and other
factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including
changes from anticipated levels of revenues, future national or regional economic and competitive conditions, difficulties in developing the
Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s
products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are
reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking
information contained in this presentation. Any forward-looking statements or information in this presentation speak only as at the date of this
presentation.
3. 3
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Company Description
ACTINIUM is an oncology focused company with proprietary
alpha and beta emitter (radiation) technology initially targeting
early and late stage leukemia. We are one of only three companies
in the world developing alpha emitters.
4. 4
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Company Overview
♦ Overall investment of $100M to develop Alpha Emitter
Technology to treat Leukemia
♦ 68 Patents (owned and in-licensed from Memorial Sloan
Kettering Cancer Center and others)
♦ Advisory Board Represents all Major Cancer Centers
including Memorial Sloan Kettering, Fred Hutchinson and
MD Anderson
♦ Iomab-B on the cusp of entering Phase III for Relapsed
and Refractory Acute Myeloid Leukemia (AML) (Patients >
55)
5. 5
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Company Overview (continued)
♦ Actimab-A in Phase I/II Trials for Newly Diagnosed AML
♦ 1 of only 3 Companies in World with Alpha Technology
♦ Fully Funded for next 12 months
♦ World Class Board of Directors
♦ Sloan Kettering Largest Shareholder and also Merck a
Shareholder
6. 6
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Financial Facts
Actinium Pharmaceuticals
Stock Ticker ATNM
Stock Exchange NYSE MKT
Market Cap 251.48M
Average 3 Month Volume 20,189
Shares Outstanding 25.32M (35.5M fully diluted)
Float 19.6M
Cash as of Dec 31, 2013 5.53M
*Pro-forma from Jan 24th, 2014 Offering $3.3M Not Included
7. 7
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Cancer Treatment Options
Treatment % 50% <10%
Pharmaceutical
Revenue %
<3% ~30%
Always a pharmaceutical
Strong IP protection
Mostly proprietary
Monoclonal Antibodies (mAbs)Radiation
External radiation majority treatment
Internal radiation has mostly no IP
Commoditized
♦
♦
♦
♦
♦
♦
Antibody Approaches Targeting Cancer Cells
α
Cancer cell
β
Range
.06mm
Range
1 - 10mm
DNA
8. 8
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
ATNM’s Proprietary Technology Platform
♦ Delivers radiation to cancer site via pharmaceutical carrier through an injection
– Antibody provides precision, targeting cancer cells specifically while avoiding normal cells
– α emitters provide killing power with a very short range for narrow targeting
– β emitters kill by crossfire which is useful in select indications
* APIT is Actinium Pharmaceutical’s Alpha Particle Immunotherapy platform technology. It does not apply to Iomab-B.
** Certain β emitters, specifically iodine 131 in Iomab-B, do not require a linker.
APIT* Technology
Antibody (targeting agent)
Chelator (linker)
α / β** emitter (killing agent)
9. 9
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Clinically Relevant α Emitters
* Clinically relevant but commercially not feasible in ATNM’s opinion.
αemitter
Platform
Potential
Half Life Stage IP Ownership
Market Cap
($mm)
Actinium 225 Yes 10 days Phase I/II Actinium Pharmaceuticals
Bismuth 213 Yes 46 minutes Phase II Actinium Pharmaceuticals
Radium 223 No 11 days Marketed Algeta
Thorium 227 Yes 18 days Preclinical Algeta
Astatine 211 * Yes 7 hours Phase II Duke University NM
Lead 212 * Yes 11 hours Phase I Areva Med NM
Bismuth 212 * Yes 1 hour Preclinical NM NM
$141
$1,601
10. 10
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Robust Intellectual Property Protection
♦ 68 Patents issued and pending
– United States 17
– International 51
♦ Eligible for orphan drug exclusivity
Area Claim Expiration Status
Platform Technology Metastases larger than 1mm 2020 Allowed
Platform Technology DOTA* labeling 2021 Issued
Drug Preparation Methods Ac-225 labeling 2029 Pending
Drug Preparation Methods Bi-213 labeling 2017/2020 Issued
Isotope Production Methods Ac-225 cyclotron production 2023/2025 Pending/Allowed
mAb Composition and Production Production of leukemia antibody 2015 Issued
Methods of Treatment Protection of toxicity 2023 Pending
* DOTA is the name of the chelator (linker) that Actinium uses to attach the antibody to the α emitter.
11. 11
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
ATNM’s Product Pipeline
s.d. – single dose
f.d. – fractionated dose (2)
1 HSCT stands for Hematopoietic Stem Cell Transplantation, a procedure in which cells capable of reconstituting normal bone marrow function are transplanted to a patient.
2 ATNM has decided to discontinue development of Bismab-A at this time due to supply, logistics and cost reasons. Actimab-A is the second generation drug of Bismab-A.
3 Properties of actinium 225 are uniquely suited for Antiangiogenesis and ATNM is considering options for further development in that area.
4 Glioblastoma (GBM) and breast cancer models are founded on an antiangiogenesis approach. Antiangiogenesis therapies starve cancerous tumors by choking off blood supplies to them.
12. 12
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Iomab-B: Next Step – Phase III Trial
♦ Experience with 250+ patients in 5 Phase I and II clinical trials
♦ In-licensed from Fred Hutchinson Cancer Center, 7 ongoing physician trials with BC8 mAb
♦ Indication is to condition bone marrow in relapsed and refractory AML patients over 55 years old
in preparation for HSCT
Iomab-B regimen Conventional Care
(high dose chemo followed by HSCT)
♦ Almost all patients eligible ♦ <10% eligible
♦ ~30% survive 1 year plus,
~20% survive 2 years plus
♦ <10% survive 1 year plus,
<2% survive 2 years plus
♦ Up to $200K per patient ♦ Up to $330K per patient
Treatment Options for Older Refractory AML Patients*
Survival:
Cost:
Treatment:
Usage:
*Source: Oran B, and Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 2012;97(12):
1916-1924. doi:10.3324/haematol.2012.066100
“Overall economic burden of total treatment costs in acute myeloid leukemia throughout the course of the disease”, Dalia Mahmoud, MBA,
Barry S. Skikne, MD, Izabela Kucmin-Bemelmans, MSc, Cathelijne Alleman, MSc and Marja Hensen, MSc, 54th ASH Annual Meeting abstract.
13. 13
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Iomab-B Phase I/II Results
♦ Only potential cure for blood cancers is HSCT, but vast majority of patients over 50 are ineligible
– Iomab-B has demonstrated ability to successfully prepare these patients for HSCT
♦ Clinical trials completed in 250+ patients with various incurable blood cancers
– In both PI and PII trials, Iomab-B led to effective treatment in patients with no other options left
All relapsed/refractory AML patients over 50 Rel/ref AML patients over 50 w/ poor cytogenetics
30%
19%
10%
0%
10%
0%
0%
5%
10%
15%
20%
25%
30%
35%
1 year 2 years
PercentageSurvival
Iomab-B HSCT (N=27)
Current HSCT (N=10)
Chemotherapy (N=61)
33%
16%
3%
0%
3%
0%
0%
5%
10%
15%
20%
25%
30%
35%
1 year 2 years
PercentageSurvival
Iomab-B HSCT (N=18)
Current HSCT (N=19)
Chemotherapy (N=95)
N = Number of patients treated;
Iomab-B results from FHCRC clinical trials;
Current HSCT and Chemotherapy results from MD Anderson outcomes analysis.
14. 14
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Iomab-B FDA Meeting Results
♦ A successful End of Phase II meeting was held with the FDA and
agreements were reached on the following
– Path to approval
– Number of studies
– Phase III trial design to support a BLA submission
– Patient population
– Study size (n)
– Primary and secondary endpoints
– Statistical considerations
15. 15
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Iomab-B Development Plan
Timeline* Worldwide Market
Indication 2014 2015 2021 2022 Potential ($mm)
Approval
Acute Myeloid Leukemia Sales Start $793
Myelodysplastic Syndrome Approval Sales Start $264
Acute Lymphoblastic Leukemia Approval Sales Start $264
Non-Hodgkin's Lymphoma and
Hodgkins Disease
Approval Sales Start $1,455
Multiple Myeloma Approval Sales Start $1,322
Total $4,098
2018 20192013 2017 20202016
I
I
II
II
III
III
III
III
III
II
II
Currently no approved treatments for Iomab-B targeted patients imply
blockbuster potential
* Phase I and Phase II represent physician trials at Fred Hutchison Cancer Research Center. Phase III trials represent ATNM sponsorship.
Source: GLOBOCAN, SEER , and the Company
16. 16
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Actimab-A vs. Current Treatments
Treatment:
Usage: ♦ 64% of patients 60+ use this
option due to lack of tolerable
alternatives
♦ 36% of patients 60+ are
eligible
♦ Potentially any AML patient
due to limited side effects
Survival: ♦ Less than 2 months ♦ Less than 6 months ♦ Limited history; Bismab-A
trials show median survival is
4x greater
Cost: ♦ $55K per patient ♦ $170K per patient ♦ $60K per patient
New Treatment Option
Supportive Care Actimab-AHigh Dose Chemotherapy
Current Treatment Options*
*Source: ARCH INTERN MED/Vol 162, July 22, 2002;
Overall Economic Burden of Total Treatment Costs in Acute Myeloid Leukemia throughout the Course of the Disease, Dalia Mahmoud,
MBA, Barry S. Skikne, MD, Izabela Kucmin-Bemelmans, MSc, Cathelijne Alleman, MSc and Marja Hensen, MSc, 54th ASH Annual Meeting.
17. 17
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Target: ♦ AML ♦ AML
Effectiveness: ♦ Proof of concept in humans + 500x more potent than Bismab-A
Clinical Stage: ♦ Excellent results in Phase II ♦ Currently in a Phase I/II Trial
Supply Chain: ♦ Complex, high COGS + Simple, 10x lower COGS
Ease of Use: ♦ Complex on site preparation + Central manufacturing
♦ Does not require additional diagnostics ♦ Does not require additional diagnostics
Bismab-A Actimab-A
Actimab-A shows superior efficacy to Bismab-A in a comparable trial
* More than 5% of bone marrow blasts signifies persistent presence of leukemia cells.
Bismab-A Profile Actimab-A Advantages
1st Generation 2nd GenerationAPIT
Platform
Bismab-A experience implies successful Actimab-A trial results
Parameter Bismab-A Actimab-A
Elimination of peripheral blasts 27% 63%
Bone Marrow blasts decrease by 50% or more 28% 50%
Bone Marrow blasts 5% or less post treatment* 0% 20%
18. 18
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Actimab-A Clinical Trial Update
♦ Started the new multicenter Phase I/II clinical trial
♦ Expanded the number of participating clinical centers:
– Memorial Sloan Kettering Cancer Center, Johns Hopkins Medicine, Fred Hutchinson Cancer
Center, University of Pennsylvania Health Center, MD Anderson Cancer Center
♦ New protocol sets lower standard than MSKCC PI Trial
– Treating newly diagnosed patients
– Introducing cytoreduction (reduces the number of cancer cells)
– New patient population is likely to respond better to treatment based on medically accepted criteria
– No toxicity outside of blood cells at doses expected to be clinically effective
♦ Targeting end of Phase II trial in 2015, preliminary data by ASH 2014
♦ No new AML drugs have been approved; unmet medical needs remain, which should
create interest from potential licensors, investors (Stemline, Marshall Edwards)
19. 19
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Market Positioning for Iomab-B, Actimab-A
Treatment Response TreatmentsDiagnosis
AML
Age >55
Complete
Response
Relapsed &
Refractory
AML
HSCT
Death
High dose
chemotherapy
Actimab-A
Complete
Response
Death
Reduced Intensity
BM Conditioning
Reduced Intensity
BM Conditioning
Iomab-B
♦ HSCT is a procedure
that restores stem cells
destroyed by high doses
of chemotherapy and/or
radiation therapy
♦ HSCT is widely used in
other forms of cancer
outside of AML
♦ ATNM can leverage its
proprietary platform for
additional HSCT
indications
Negative Response
ATNM Pipeline Drugs
Positive Response
Current Treatments
ATNM products target both treatment stages for AML patients over 55 years of age
20. 20
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Market Potential of Product Pipeline
♦ The $1.3 billion Bone Marrow Transplant (BMT) market in
the US is largely unaddressed by novel pharmaceutical drug
companies
♦ BMT is the fastest growing hospital procedure in the US
– ~20,000 of the ~60,000 BMTs in 2010 were
performed in the US
♦ Sustained growth in patients treated over 55 yrs old
– 8% in 2000 to 21% in 2005 and 27% in 2007
♦ Acute Myeloid Leukemia is the deadliest form of
leukemia
– 55% of AML patients are over 65 years old
– Disease is worse in older people
– Insufficient treatment options are available in the
marketplace
– Treatment kills as many patients as it helps due to
toxicity
HSCT (Iomab-B) AML (Actimab-A)
1. Target market includes USA, EU and Japan
2. Market Potential calculated based on assumption that Actinium products for solid cancer indications will be priced at $20,000 per treatment;
HSCT preparation product will be priced at $85,000 per treatment; AML product will be priced at $60,000 per treatment; and GBM product
will be priced at $60,000 per treatment. Estimates based on independent third party research and adjusted for lower pricing in non-US
markets.
# Cancer Indication Cases/Yr. in
target market1
Target
Population
Worldwide Market
Potential ($mm)2
1st
HSCT (Bone Marrow) 48,000 48,000 $4,100
2nd
Acute Myeloid Leukemia (AML) 41,600 24,000 $920
3rd
Glioblastoma Multiforme (GBM) 26,500 26,500 $1,100
4th
Prostate Cancer (metastatic) 591,000 298,455 $5,959
5th
Metastatic Colorectal Cancer 536,000 241,200 $4,824
Source: GLOBOCAN, SEER , and the Company
21. 21
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Recent Phase I/Phase II Cancer Licensing Deals
Company
Phase at
Signing
Deal
Size
Upfront
Fee Date Deal Description
Algeta Phase II $800 $61 9/3/2009 Algeta signs $800 million deal with Bayer for
Alpharadin in prostate cancer bone metastases
Areva Med Phase I NA NA 7/27/2012 Areva Med signs agreement with Roche for an
alpha radio-immunotherapy platform
(Lead-212) in malignant cancer
Endocyte Phase II $1,000 $120 4/16/2012 Endocyte signs agreement with Merck for
Vintafolide (EC145)
Genmab Phase I/II $1,100 $55 8/30/2012 Genmab signs agreement with Johnson & Johnson
for Daratumumab in multiple myeloma
Innate Pharma Phase I $465 $35 7/6/2011 Innate Pharma signs agreement with Bristol-Myers
Squibb for AML antibody IPH2102
Medivation Phase II $765 $110 10/27/2009 Medivation signs agreement with Astellas Pharma
for MDV3100
Threshold Pharmaceuticals Phase II $592 $25 2/3/2012 Threshold Pharmaceuticals signs agreement with
Merck KGaA for TH-302 in AML and other
indications
Topotarget Phase II $350 $30 2/2/2010 TopoTarget signs agreement with Spectrum
Pharmaceuticals for Belinostat
All Figures in USD ($mm)
Rich deals available for novel technologies with proof of concept
Source: Medtrack, Company Reports.
22. 22
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Near-term Value Drivers
♦ Iomab-B
! Complete PIII Protocol
! Start cGMP mAb mfg
! Start drug mfg cGMP process
– Complete cGMP mAb mfg
– Complete Drug mfg cGMP
– Submit PIII IND
– Start PIII
♦ Actimab-A
– Complete PI trial
– Complete mfg. improvements
– Start and complete PII trial
♦ Third Program
! Start preclinical development
– Complete preclinical development
– File IND
Multiple development milestones in next 12-18 months as ATNM’s products advance
to a stage of development
! Uplisting to NYSE MKT
(Accomplished March 26, 2014)
♦ Additional Analyst Coverage
♦ Collaborations
23. 23
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Core Team & Advisors
Team Background
Kaushik J. Dave, PhD, MBA
President and CEO,
♦ 25 years of Pharma and Biotech industry at both big Pharma and small startups.
♦ Formerly, EVP at Antares Pharma Inc., VP at Palatin Technologies Inc., and Big Pharma (Schering-Plough and Merck)
♦ BPharm from University of Bath (UK), PhD from University of Kansas, MBA from Wharton School at The University of
Pennsylvania;
Gerri Henwood
Chief Development Officer
♦ President & Founder of Malvern Consulting Group and President & CEO of Recro Pharma
♦ Former Founder, President & CEO of Auxilium Pharmaceuticals, Inc (NASDAQ:AUXL)
♦ Former Founder & CEO of IBAH (formerly NASDAQ listed; acquired by Omnicare (NYSE))
♦ Board of Directors of Alkermes, Inc. (NASDAQ:ALKS), Garnet BioTherapeutics, Inc., LZ Therapeutics, Inc., and MAP
Pharmaceuticals, Inc.(NASDAQ:MAPP)
Dragan Cicic, MD, MBA
COO & CMO
♦ 9 years at Actinium Pharmaceuticals (ATNM), previously serving as Medical Director
♦ Formerly a strategic consultant at QED Technologies and an investment banker at SG Cowen Securities
♦ MBA, Wharton School at The University of Pennsylvania; MD, School of Medicine at The Belgrade University
♦ Nieman Fellow at Harvard University
Richard Steinhart BBA, MBA
Director
♦ Industry Consultant
♦ Formerly Senior Vice President, Finance and Chief Financial Officer of MELA Sciences Inc.
♦ Formerly Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and
management consulting firm focused on healthcare and technology companies.
♦ B.B.A. and M.B.A., Pace University
Sergio Traversa, PharmD, MBA
Director
♦ CEO of Relmada Therapeutics, Inc.
♦ 25+ years of management and investment experience in healthcare as a Portfolio Manager & Sr. Pharmaceutical Analyst (Mehta &
Isaly, ING Barings, Merlin BioMed & Rx Capital) and in industry (CNS at Eli Lilly, Pfizer)
♦ MBA, Finance at New York University, Laurea of Pharmacy at the University of Turin
David Nicholson, PhD
Director
♦ Head of R&D, Bayer CropScience
♦ Formerly Sr. VP and Head Worldwide Licensing and Knowledge Management at Merck
♦ Formerly Head of R&D at Organon prior to acquisition by Schering-Plough
♦ Ph.D., University of Wales
Sandesh Seth, MS, MBA
Chairman of the Board
♦ Head of Healthcare Investment Banking at Laidlaw & Company (UK) Ltd.
♦ 20+ years experience in investment banking (Cowen & Co.), equity research (Bear Stearns, Commonwealth Associates) and in
industry (Pfizer, Warner-Lambert, SmithKline)
♦ MBA, Finance at New York University; MS, Pharmaceutical Sciences at University of Oklahoma Health Center
24. 24
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Clinical Advisory Board
Treatment Center Advisory Board Members
Memorial Sloan Kettering
Cancer Center
David Scheinberg, M.D., PhD
Chairman of Experimental Therapeutics at MSKCC
Vincent Astor Chair
Scientific Co-Founder
Fred Hutchinson
Cancer Center
Elihu H. Estey, M.D.
Professor of Medicine
Division of Hematology
University of Washington School of Medicine
WHO Treatment guidelines for AML
John Pagel, M.D., PhD
Assistant Professor/Assistant Member
Department of Medicine, Division of Oncology
Lead Investigator for Iomab-B
MD Anderson Cancer Center Hagop Kantarjian, M.D.
Professor of Leukemia
Department Chair, Department of Leukemia
Division of Cancer Medicine
University of Texas
Key Investigator for Actimab-A
Johns Hopkins Medicine Richard Wahl, M.D.
Director, Division of Nuclear Medicine/PET
Professor of Nuclear Medicine
Professor of Radiology and Oncology
Vice Chairman, Technology and New Business Development
Department of Radiology
“Father of PET Imaging”
Judith Karp, M.D.
Professor of Oncology
Director, Adult Leukemia Program, Division of
Hematologic Malignancies
The Sidney Kimmel Comprehensive Cancer Center
Columbia University
Medical Center
Joseph G. Jurcic, M.D.
Professor of Clinical Medicine
Director of Hematologic Malignancies
Hematology/Oncology Division
CAB Chairman, Lead Investigator for Actimab-A trials
University of Pennsylvania
Health System
Alexander Perl, M.D.
Assistant Professor of Medicine
Division of Hematology/Oncology
25. 25
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
Highlights
! Prior clinical data for both Iomab-B and Actimab-A favor successful
trial results
! Breakthrough therapy potential implies successful market penetration
for both Iomab-B and Actimab-A
! APIT platform poised to deliver multiple blockbuster cancer drugs
! An expert team possessing the vision and desire to enhance
shareholder value
! Positioned to benefit from increased market recognition of targeted
payload therapies and an initial high-value, niche product model